GlycoGenesys, Inc. to Announce Clinical Data and Present at Roth Capital Partners New York Conference September 8th, 2005

GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology
company focused on carbohydrate-based drug development, today
announced that it will announce preliminary clinical data from its
Phase I dose escalation trial the morning of September 8, 2005 and
present at the Roth Capital Partners New York Conference later that
morning. GlycoGenesys, Inc. CEO Bradley J. Carver, is scheduled to
give the presentation.

   Presentation and Web Casting Information

   Roth Capital Partners New York Conference. The Westin New York at
Time Square. Broadway II suite, 3rd Floor at 11:00 a.m. E.D.T.
Presentation will be web cast live and will be available for replay.
Please use the following link to access the web cast or its replay:
http://www.wsw.com/webcast/roth6/glgs/ 

   GlycoGenesys, Inc.

   GlycoGenesys, Inc. is a biotechnology company that develops and
licenses compounds based on glycobiology. The Company's drug candidate
GCS-100, a unique compound to treat cancer, has been evaluated in
previous clinical trials at low dose levels in patients with
colorectal, pancreatic and other solid tumors with stable disease and
partial response documented. The Company currently is conducting a
Phase I dose escalation trial to evaluate higher dose levels of
GCS-100LE, a low ethanol formulation of GCS- 100, at Sharp Memorial
Hospital, Clinical Oncology Research in San Diego, California and the
Arizona Cancer Center in both Tucson and Scottsdale, Arizona. In
addition, GCS-100LE is being evaluated in a Phase I/II trial for
multiple myeloma. Further clinical trials are planned for 2005, 2006
and 2007. Further information is available on GlycoGenesys' web site:
www.glycogenesys.com. 

   Safe Harbor Statement

   Any statements contained in this release that relate to future
plans, events or performance are forward-looking statements that
involve risks and uncertainties, including, but not limited to, risks
of product development (such as failure to demonstrate efficacy or
safety), risk related to FDA and other regulatory procedures, market
acceptance risks, the impact of competitive products and pricing, the
results of current and future licensing, joint ventures and other
collaborative relationships, risks relating to raising sufficient
capital to fund the Company's operations, developments regarding
intellectual property rights and litigation, and other risks
identified in the Company's Securities and Exchange Commission
filings. Actual results, events or performance may differ materially.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as the date hereof. The
Company undertakes no obligation to publicly release the results of
any revisions to these forward- looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.